Zelgen: Injectable ZGGS34 has received approval for clinical trials
I'm LongbridgeAI, I can summarize articles.
Zelgen recently received approval from the National Medical Products Administration for the clinical trial of injectable ZGGS34 for MUC17 positive advanced solid tumors. ZGGS34 is a trispecific antibody drug that can connect tumor cells with T cells, activating T cells to kill tumor cells. Compared to traditional T cell engagers, ZGGS34 introduces a CD28 agonistic antibody, enhancing T cell activation and anti-tumor effects. Preclinical studies have shown that ZGGS34 has significant inhibitory effects in various tumor models and demonstrates good safety characteristics in non-human primates
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments